Lysostaphin: an antistaphylococcal agent

被引：107
作者：
Kumar, Jaspal K. [1 ]
机构：
[1] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore
来源：
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY | 2008年 / 80卷 / 04期
关键词：
Staphylococcus aureus; MRSA; lysostaphin; therapeutics;
D O I：
10.1007/s00253-008-1579-y
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Lysostaphin is a zinc metalloenzyme which has a specific lytic action against Staphylococcus aureus. Lysostaphin has activities of three enzymes namely, glycylglycine endopeptidase, endo-beta-N-acetyl glucosamidase and N-acteyl muramyl-L-alanine amidase. Glycylglycine endopeptidase specifically cleaves the glycine-glycine bonds, unique to the interpeptide cross-bridge of the S. aureus cell wall. Due to its unique specificity, lysostaphin could have high potential in the treatment of antibiotic-resistant staphylococcal infections. This review article presents a current understanding of the lysostaphin and its applications in therapeutic agent as a treatment against antibiotic-resistant S. aureus and methicillin-resistant S. aureus (MRSA) infections, either alone or in combination with other antibiotics.
引用
收藏
页码：555 / 561
页数：7
相关论文
共 73 条
[1]   Staphylococcus aureus bacteremia -: Consider the source. [J].
Archer, GL ;
Climo, MW .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (01) :55-56
[2]   Target cell specificity of a bacteriocin molecule: A C-terminal signal directs lysostaphin to the cell wall of Staphylococcus aureus [J].
Baba, T ;
Schneewind, O .
EMBO JOURNAL, 1996, 15 (18) :4789-4797
[3]   Why are pathogenic staphylococci so lysozyme resistant?: The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus [J].
Bera, A ;
Herbert, S ;
Jakob, A ;
Vollmer, W ;
Götz, F .
MOLECULAR MICROBIOLOGY, 2005, 55 (03) :778-787
[4]   EFFECTS OF LYSOSTAPHIN ON STAPHYLOCOCCUS-AUREUS INFECTIONS OF THE MOUSE MAMMARY-GLAND [J].
BRAMLEY, AJ ;
FOSTER, R .
RESEARCH IN VETERINARY SCIENCE, 1990, 49 (01) :120-121
[5]   LYSOSTAPHIN - ENZYMATIC MODE OF ACTION [J].
BROWDER, HP ;
ZYGMUNT, WA ;
YOUNG, JR ;
TAVORMIN.PA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1965, 19 (03) :383-&
[6]   ASPECTS OF EPIDEMIOLOGY OF BOVINE STAPHYLOCOCCAL MASTITIS [J].
BUDDLE, BM ;
COOOPER, MG .
NEW ZEALAND VETERINARY JOURNAL, 1978, 26 (12) :296-&
[7]   Application of lysostaphin-producing lactobacilli to control staphylococcal food poisoning in meat products [J].
Cavadini, C ;
Hertel, C ;
Hammes, WP .
JOURNAL OF FOOD PROTECTION, 1998, 61 (04) :419-424
[8]   HIGH-LEVEL POTENTIATION OF LYSOSTAPHIN ANTI-STAPHYLOCOCCAL ACTIVITY BY LYSOZYME [J].
CISANI, G ;
VARALDO, PE ;
GRAZI, G ;
SORO, O .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 21 (04) :531-535
[9]   Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus [J].
Climo, MW ;
Ehlert, K ;
Archer, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (05) :1431-1437
[10]   Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis [J].
Climo, MW ;
Patron, RL ;
Goldstein, BP ;
Archer, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) :1355-1360
12345678